



RepliCel™


Using Cells for Healing

OTCPK: REPCF | TSXV: RP | FRA:P6P2

A Revolution in Sports Medicine and Aesthetics.

We are a regenerative medicine company with innovative cell therapy technology providing unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.

Three applications, two biologics, one game-changing delivery platform



RCT-01 Tendon Repair
(Partnered with YOFOTO in Greater China; active licensing discussions in Japan)

POSITIVE PHASE CLINICAL DATA Randomized (3:1) double-blind, placebo-controlled trial at UBC Sports Medicine Clinic (8 participants)

Primary Endpoint: Safety
Secondary Endpoint: Efficacy at 6 months (function, pain, regeneration, blood flow)



RCS-01 Dermal Rejuvenation
(Partnered with YOFOTO in Greater China; active licensing discussions in Japan)

POSITIVE PHASE 1 CLINICAL DATA Phase 1/2 randomized, double-blinded, placebo-controlled trial at IUF Leibniz-Institut für umweltmedizinische Forschung (Germany) {19 participants}

Primary Endpoint: Safety
Secondary Endpoint: Efficacy at 6 months (biomarkers related so collagen & skin health)



RCH-01 Pattern Baldness
(Partnered with Shisiedo in Asia)

POSITIVE PHASE 1 & 2 CLINICAL DATA Randomized, double-blind, placebo-controlled, dose-finding clinical study. {84 participants}

Primary Endpoint: Hair Density Dose, Safety



RCI-02 PATENTED DERMAL INJECTION DEVICE

The RCI-02 dermal injector is designed to deliver cells, dermal fillers, drug and biologics.

- Digital controls program for depth, volume, rate of dispersion
- Provides exact repeatable dispersion across 3 dimensions
- Removes human variability
- Built-in Peltier element reduces need for anesthetics
- Near-term commercial launch



Poised for growth and momentum

Potential to Revolutionize Sports Medicine and Aesthetics

This innovative cell therapy technology has the potential to revolutionize two large consumer-pay markets where few solutions exist.

The Only Regenerative Medicine Company Using Hair Follicle Cell Therapy

We are the only Company using cells derived from hair follicles to potentially heal damaged skin and tendon tissue—offering hope for people with conditions beyond repair.

Multiple Assets Addressing Conditions With Unmet Need

Multi-product portfolio diversifies risk over several programs in two different markets.

Near-Term Commercial Launch And Revenue Catalysts

Anticipated approval to commercially launch the dermal injector in 2021 and potential to launch multiple clinical products in Japan by 2023.

Multiple Assets Across Large Market Applications with Key Partnership in Place

Positive phase 1 and 2 clinical data and dermal injector prototypes focused on skin, tendon and hair health (all large markets).

Strategic Partnerships Contributing Value

MainPointe Pharmaceuticals to obtain FDA approval for RCI-01 and distribute it in the USA.

YOFOTO to co-develop and market RCT-01 and RCS-01 as well as distribute RCI-02, in Greater China.

Shiseido to co-develop and market RCH-01 in Asia.

Capital Structure (as at Feb 2021)

Current market cap. (approx.)	~\$15.1M
Total money raised through equity to-date	~\$34M
Total revenue to-date (upfront licensing payments)	\$5.24M
Current Monthly Burn Rate	~\$305,000
Shares Issued and Outstanding	34.7M

Board and Management Team

David Hall
Chairman

Directors:

Peter Lowry

Andrew Schutte

Peter Lewis

Lee Buckler

R. Lee Buckler, B. Ed, LLB
President, CEO & Director

Dr. Rolf Hoffman, MD
Chief Medical Officer

Dr. Kevin McElwee, PhD Chief Scientific Officer

Simon Ma CA
Chief Financial Officer